Back to Search Start Over

ADA activity is decreased in lymphocytes from patients with advanced stage of lung cancer.

Authors :
Zanini D
Manfredi LH
Pelinson LP
Pimentel VC
Cardoso AM
Carmo Araújo Gonçalves VD
Santos CBD
Gutierres JM
Morsch VM
Leal DBR
Schetinger MRC
Source :
Medical oncology (Northwood, London, England) [Med Oncol] 2019 Aug 02; Vol. 36 (9), pp. 78. Date of Electronic Publication: 2019 Aug 02.
Publication Year :
2019

Abstract

Cigarette smoking is directly associated with lung cancer. Non-small cell lung carcinoma (NSCLC) represents approximately 80% from all types of lung cancer. This latter is hard to diagnose and to treat due to the lack of symptoms in early stages of the disease. The aim of this study was to evaluate ADA activity and the expression of P2X7, A1, and A2A receptors and in lymphocytes. In addition, the profile of pro-inflammatory and anti-inflammatory cytokines serum levels of patients with lung cancer in advanced stage was evaluated. Patients (n = 13) previously treated for lung cancer at stage IV (UICC) with chemotherapy had their blood collected. Cancer patients showed a decrease in ADA activity and an increase in A1 receptor expression in lymphocytes when compared to the control group. Moreover, patients exhibited an increase in IL-6 and TNF-α, while IL-17 and INF-ϒ serum levels were lower in patients with lung cancer. The decreased ADA activity and the increase in A1 receptor expression may contribute to adenosine pro-tumor effects by increasing IL-6 and TNF-α and decreasing IL-17 and INF-γ serum levels. Our data show an indirect evidence that purinergic signaling may have a role in promoting a profile of cytokines levels that favors tumor progression.

Details

Language :
English
ISSN :
1559-131X
Volume :
36
Issue :
9
Database :
MEDLINE
Journal :
Medical oncology (Northwood, London, England)
Publication Type :
Academic Journal
Accession number :
31375946
Full Text :
https://doi.org/10.1007/s12032-019-1301-1